BRAF and neoplasm: Therefore, our study suggests that BRAF V600E constitutively activates mitochondrial ERK, thereby inhibiting GSK‐3‐dependent CypD phosphorylation, and thus making BRAF V600E mutant tumour cells more resistant to mPTP pore opening and subsequent cell death.